Guidance for Industry; Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production

Jitendra Pund provides specific technical recommendations for the "Investigating Out of Specification (OOS) Test Results for Pharmaceutical Production Guidance for Industry." The commenter argues for a structured, step-by-step risk assessment process that includes initial laboratory investigations, full-scale reviews, and the use of specific tools like FMEA and fishbone diagrams to ensure patient safety and regulatory compliance.

The commenter supports the guidance but argues that the FDA should issue a clarification to prevent it from being misapplied in non-manufacturing contexts (such as forensic or clinical testing). They emphasize that the guidance must be strictly followed regarding mandatory investigations, the prohibition of "testing into compliance," and the requirement for documented assignable causes before invalidating any out-of-specification results.

The commenter argues that the proposed guidance is insufficient because it fails to specify which phases of clinical trials (Phase I or II) should be considered when investigating Out-of-Specification (OOS) results. They suggest that factors like improper storage of Active Pharmaceutical Ingredients (API) could lead to degradation and should be explicitly addressed in the guidelines.

Jitendra Pund provides specific technical recommendations for the Phase I investigation of Out-of-Specification (OOS) test results in pharmaceutical production. The commenter suggests specific protocols for evaluating contamination, systematic hypothesis testing, the use of expired solutions for investigation, and the requirements for retesting when laboratory errors are identified.

The commenter suggests a structural change to the guidance to move a general reporting requirement out of the "Outlier Tests" subsection. They also request that the document include more specific guidance regarding the responsibilities of contract laboratories during investigations.

The Association for Accessible Medicines (AAM), representing the generic pharmaceutical industry, supports the finalized guidance on investigating Out-of-Specification (OOS) test results. While they generally applaud the guidance, they request the reinstatement of a 2006 statement regarding the auxiliary use of outlier tests in investigations.